[go: up one dir, main page]

Expression of type 1 corticotropin-releasing factor receptor in the guinea pig enteric nervous system

J Comp Neurol. 2005 Jan 17;481(3):284-98. doi: 10.1002/cne.20370.

Abstract

Reverse transcription-polymerase chain reaction (RT-PCR), immunohistochemistry, electrophysiological recording, and intraneuronal injection of the neuronal tracer biocytin were integrated in a study of the functional expression of corticotropin-releasing factor (CRF) receptors in the guinea pig enteric nervous system. RT-PCR revealed expression of CRF1 receptor mRNA, but not CRF2, in both myenteric and submucosal plexuses. Immunoreactivity for the CRF1 receptor was distributed widely in the myenteric plexus of the stomach and small and large intestine and in the submucosal plexus of the small and large intestine. CRF1 receptor immunoreactivity was coexpressed with calbindin, choline acetyltransferase, and substance P in the myenteric plexus. In the submucosal plexus, CRF1 receptor immunoreactivity was found in neurons that expressed calbindin, substance P, choline acetyltransferase, or neuropeptide Y. Application of CRF evoked slowly activating depolarizing responses associated with elevated excitability in both myenteric and submucosal neurons. Histological analysis of biocytin-filled neurons revealed that both uniaxonal neurons with S-type electrophysiological behavior and neurons with AH-type electrophysiological behavior and Dogiel II morphology responded to CRF. The CRF-evoked depolarizing responses were suppressed by the CRF1/CRF2 receptor antagonist astressin and the selective CRF1 receptor antagonist NBI27914 and were unaffected by the selective CRF2 receptor antagonist antisauvagine-30. The findings support the hypothesis that the CRF1 receptor mediates the excitatory actions of CRF on neurons in the enteric nervous system. Actions on enteric neurons might underlie the neural mechanisms by which stress-related release of CRF in the periphery alters intestinal propulsive motor function, mucosal secretion, and barrier functions.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • Action Potentials / drug effects
  • Action Potentials / physiology
  • Aniline Compounds / pharmacology
  • Animals
  • Calbindins
  • Choline O-Acetyltransferase / metabolism
  • Corticotropin-Releasing Hormone / metabolism
  • Corticotropin-Releasing Hormone / pharmacology
  • Enteric Nervous System / cytology
  • Enteric Nervous System / drug effects
  • Enteric Nervous System / metabolism*
  • Gastrointestinal Tract / innervation*
  • Guinea Pigs
  • Lysine / analogs & derivatives*
  • Male
  • Myenteric Plexus / cytology
  • Myenteric Plexus / drug effects
  • Myenteric Plexus / metabolism
  • Neurons / cytology
  • Neurons / drug effects
  • Neurons / metabolism*
  • Neuropeptide Y / metabolism
  • Peptide Fragments / pharmacology
  • Pyrimidines / pharmacology
  • RNA, Messenger / metabolism
  • Receptors, Corticotropin-Releasing Hormone / drug effects
  • Receptors, Corticotropin-Releasing Hormone / genetics
  • Receptors, Corticotropin-Releasing Hormone / metabolism*
  • S100 Calcium Binding Protein G / metabolism
  • Stress, Physiological / metabolism*
  • Stress, Physiological / physiopathology
  • Submucous Plexus / cytology
  • Submucous Plexus / drug effects
  • Submucous Plexus / metabolism
  • Substance P / metabolism

Substances

  • 2-methyl-4-(N-propyl-N-cycloproanemethylamino)-5-chloro-6-(2,4,6-trichloranilino)pyrimidine
  • Aniline Compounds
  • Calbindins
  • Neuropeptide Y
  • Peptide Fragments
  • Pyrimidines
  • RNA, Messenger
  • Receptors, Corticotropin-Releasing Hormone
  • S100 Calcium Binding Protein G
  • astressin
  • Substance P
  • CRF receptor type 1
  • Corticotropin-Releasing Hormone
  • Choline O-Acetyltransferase
  • biocytin
  • Lysine